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Summary
It is well known that oocytes can reprogram differentiated cells, allowing animal cloning by
nuclear transfer. We have recently shown that fertilized zygotes retain reprogramming activities
[1], suggesting such activities might also persist in cleavage stage embryos. We have used
chromosome transplantation techniques to investigate whether the blastomeres of two-cell stage
mouse embryos can reprogram more differentiated cells. When chromosomes from one of the two
blastomeres were replaced with the chromosomes of an embryonic or CD4+ T-lymphocyte donor
cell, we observed nuclear reprogramming and efficient contribution of the manipulated cell to the
developing blastocyst. Embryos produced by this method could be used to derive stem cell lines
and also developed to term, generating mosaic “cloned” animals. These results demonstrate that
blastomeres retain reprogramming activities and support the notion that discarded human
preimplantation embryos may be useful recipients for the production of genetically tailored human
embryonic stem cell lines.
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Results and Discussion
Reprogramming by nuclear transfer allows the generation of animals and embryonic stem
cell lines from somatic cells [2]. This approach, if successful with human cells, would allow
the production of human stem cell lines from individual patients for personalized medicine
or in vitro modeling of their condition [3–5]. However, attempts to produce human
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embryonic stem cell lines by nuclear transfer have thus far been unsuccessful, in part due to
the limited availability of human oocytes.
Reprogramming by nuclear transfer is only successful under certain specific conditions,
making it difficult to source the appropriate recipient cell-types. Reprogramming and
embryonic development can occur in animals after transfer of somatic nuclei into oocytes
and zygotes in metaphase of the cell cycle, but fails after transfer during interphase [6–8].
Nuclear transfer into embryonic blastomeres enucleated in interphase has also been
attempted, but failed to demonstrated reprogramming activities [9, 10]. In particular, no
development was observed after transfer of inner cell mass nuclei into 2-cell stage embryos
enucleated in interphase [10].
Our results suggest that one key to successful reprogramming is the removal of the recipient
cell genome at metaphase when the nuclear envelope is broken down and chromosomes are
condensed (Fig. 1a). This suggests that reprogramming might also be possible in cell types
other than oocytes or zygotes, if and only if their genome is removed in mitosis. Because
they are relatively large embryonic cells, we first considered whether the blastomeres in a
two-cell mouse embryo harbored reprogramming activities.
To determine whether blastomeres contained reprogramming activities, we sought to stably
but reversibly arrest them in mitosis for chromosome transfer studies. We isolated fertilized
zygotes from superovulated mice and cultured them in vitro to the two-cell stage and then
observed the embryos for entry into the second mitosis. The two blastomeres usually entered
mitosis between 48 and 54 hours after administration of the hormone trigger for ovulation.
Shortly after mitotic entry, the embryos divided to the 4-cell stage. To find the optimal
conditions in which two-cell embryos could be arrested in mitosis, we cultured them in the
presence of several nocodazole concentrations (Supplemental Table 1). Mouse 2-cell
embryos required similar or slightly higher nocodazole concentrations for mitotic arrest then
had zygotes [11]. To determine whether cell-cycle arrest was compatible with embryo
viability, we released embryos from the mitotic block and allowed these embryos to develop
in vitro to the blastocyst stage. We found that 32/35 embryos reached the blastocyst stage
(91%), indicating that mitotic arrest with nocodazole did not significantly compromise later
development. This finding was consistent with previous studies, which also suggested that a
transient arrest in mitosis by nocodazole was non-toxic to the embryo [12].
When two-cell embryos were treated with 0.1µg/ml of nocodazole, we observed that they
formed an irregular and unstable spindle that was presumably too disorganized to allow
mitotic progression (Supplemental Fig. 1). Although the spindle was disorganized enough to
cause mitotic arrest, it was still visible under Hoffman modulation contrast optics (Fig. 1c).
When these two-cell embryos were further treated with cytochalasin B, to depolymerize the
actin cytoskeleton, the spindle complex with attached chromosomes could still be
indentified and removed by micromanipulation (Fig. 1D). In all cases, when the spindle was
extracted from one of the two blastomeres, staining with the DNA dye Hoechst 33342
demonstrated that the chromosomes were also successfully removed. We initially removed
the chromosomes from only one of the two blastomeres and left the other blastomere intact
because it would allow a direct comparison of developmental potential of the transferred
with the non-transferred blastomere.
To optimize chromosome transfer into blastomeres and to determine whether they contained
reprogramming activities, we arrested mouse ES cells in mitosis with nocodazole and
injected their chromosomes into the enucleated blastomere (Fig. 1e, Supplemental Movie).
To allow fate-mapping of the blastomere that had undergone nuclear transplant we used
donor cells that expressed a histone H2B-cherry fluorescent fusion protein. Therefore the
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descendents of the nuclear transfer blastomere all possessed red fluorescent chromosomes
and nuclei, allowing their identification within the embryo (Fig 1e–h). Upon release from
mitotic arrest, both the transferred and the unmanipulated blastomeres completed mitosis
and the embryos cleaved to the 4-cell stage. As expected, two cells within the embryo
displayed H2B-cherry fluorescence, indicating that they carried the donor cell chromosomes
(Fig. 1f). We found that these 4-cell embryos continued to develop efficiently in vitro to
both the morula and blastocyst stages (Fig. 1g, h, Table 1).
To exclude that this development depended on the presence of the non-manipulated
blastomere, we generated embryos that were entirely derived from the donor genome. To do
so, the two blastomeres were fused at the 2-cell stage, resulting in a tetraploid 2-cell stage
embryo (Fig 2a). At mitosis, the tetraploid genome was removed and replaced by a diploid
genome of an ES cell. These manipulated embryos cleaved to the 2-cell stage and efficiently
proceeded in development to the blastocyst stage (8/11, or 72%). All nuclei of both
trophectoderm and ICM expressed H2B-cherry, indicating that they were entirely derived
from the injected donor chromosomes (Fig. 2b). Cavitation of the blastocyst is mediated by
the expression of a set of novel genes that include a Na/K-ATPase and aquaporin which
drive the movement of water across the trophectoderm cell layer to form a fluid-filled
blastocoel [13]. Therefore, the ES donor cell had clearly been reprogrammed to express a set
of novel genes to form a functional cell type.
If the blastomere was able to reprogram the ES cell chromosomes, then the cells descended
from the chromosome transfer blastomere might be expected to give rise to both the inner
cell mass (ICM), from which ES cells are derived, and to the trophectoderm, which ES cells
cannot normally generate. If reprogramming activities are no longer present in the mitotic
cytoplasm of blastomeres, then blastomeres receiving ES cell chromosomes might only
contribute to the ICM. To determine the relative contribution of the transferred blastomere
to the trophectoderm and inner cell mass (ICM), blastocysts were stained with the DNA dye
Hoechst 33342 and with antibodies specific to the ICM specific protein Oct4 (Fig. 3a).
Following staining, the number of red fluorescent cells in both the Oct4 positive (ICM) and
Oct4 negative (trophectoderm) compartments were determined (Fig. 3b). We observed that
in all blastocysts (11/11) the chromosome transfer blastomere contributed to both the ICM
and trophectoderm, indicating that cellular reprogramming from an ES cell to trophectoderm
identity had been allowed to occur. We further reasoned that if the reprogramming activities
of the two-cell embryo were weaker or diminished, then the transferred blastomere might
preferentially give rise to the ICM. However, we found no statistical evidence for such a
bias. 50% of TE cells and 43% of ICM cells in the blastocyst were derived from the nuclear
transfer blastomere (Fig. 3b). In addition and over all, we found that the total number of
cherry positive cells derived from the manipulated blastomere was very similar or equal to
the total number of cells from the untouched blastomere. This result suggests that the
chromosome transfer method had little effect on the overall proportion of cells that the two
blastomeres contributed to the blastocyst and that reprogramming was relatively complete.
To test whether the chromosome transfer blastomere could further contribute to
development after implantation, we transferred blastocysts to pseudopregnant recipient
females, allowed the embryos to be carried to term and then assessed chimerism in the
resulting offspring. In these experiments, the recipient embryos were isolated from a mouse
strain with a black coat color while the donor cells were derived from a strain with an agouti
(brown) coat. We performed embryo transfer with a total of 111 blastocysts that displayed
red fluorescence and therefore had significant contribution from the nuclear transfer
blastomere. After embryo transfer, a total of 7 pups were delivered by cesarean section, all
of which survived to adulthood. Respiratory failure as observed after nuclear transfer into
oocytes or zygotes was not observed [11, 14]. Five of these 7 mice had a black coat color,
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suggesting that they were predominantly or entirely derived from the unmanipulated
recipient blastomere. However, in one animal, 30% of the coat was agouti and in the last
animal, the coat color was exclusively agouti (Fig. 3c). The agouti coat color in these
animals indicated that that they were chimeric “cloned” animals composed of both
reprogrammed and normal cells.
To determine whether cells carrying the donor-cell genome had contributed widely to the
development of the two chrimeric “cloned” animals, histological analysis was performed.
We found that red fluorescent cells of donor origin, contributed significantly to the lungs,
intestine and the skin (Fig. 3d). These results demonstrate that cells reprogrammed by
blastomere nuclear transfer cannot only contribute significantly to a developing embryo but
also that they are not necessarily outcompeted by normal embryonic cells.
Since the inception of in vitro fertilization, more than 400,000 embryos have been placed in
frozen storage by couples undergoing assisted reproduction treatment [15]. Recent studies
suggest that the vast majority of these embryos remain in storage even though they are no
longer needed for reproductive purposes. Furthermore, 60% of the couples controlling the
disposition of these embryos would prefer to have them donated for stem cell research rather
than see them donated to another couple or simply discarded [16]. Although a small
percentage of human embryos are frozen at the one cell stage a majority of embryos are
frozen during cleavage stage of preimplantation development. Therefore, if methods for
reprogramming somatic cells using chromosome transfer into blastomeres could be
perfected, a conservative estimate would suggest that more than 100,000 embryos would be
readily available for human reprogramming attempts.
However, if blastomere nuclear transfer is to be useful for the production of genetically
tailored human embryonic stem cell lines, then it must be shown that ES cell lines can be
derived from blastocysts that result from this approach and it must be demonstrated that
blastomeres can reprogram terminally differentiated adult cells.
To determine whether ES cell lines could be derived from embryos created by blastomere
chromosome transfer, 14 chimeric blastocysts were placed in culture on mouse embryonic
fibroblasts for attempts at ES cell line derivation. Each of the embryos adhered to the feeder
layer and 7 gave rise to ICM outgrowths. We found that attachment sites and ICM
outgrowths consisted of both red fluorescent cells derived from the nuclear transfer
blastomere, as well as non-fluorescent cells derived from the unmanipulated blastomere
(Fig. 3e). 6 of the 7 blastocysts gave rise to ES cell cultures and 3 of these contained ES
cells derived from both the chromosome transfer blastomere (Cherry positive colony)(Fig.
3e). When red fluorescent colonies in these cultures were manually picked and expanded
into pure cultures, PCR confirmed that they contained the donor genome. Furthermore,
nuclear transfer ES cell lines expressed the pluripotency transcription factor Oct4 (Fig. 3g)
and contained a normal karyotype of 40 mouse chromosomes (Fig. 3f). And when injected
into blastocysts, these ES cells gave rise to chimeric mice (Fig. 2h).
We next sought to demonstrate that the blastomeres of the two-cell stage embryo could
reprogram a terminally differentiated adult cell. T- lymphocytes are terminally differentiated
cells, which can be reprogrammed, but only at a very low efficiency [17, 18]. We therefore
chose T-lymphocytes as donor cells because their reprogramming would be a stringent assay
for reprogramming. To assess reprogramming of the T-cell genome, we used donor cells
carrying a transgenic reporter in which regulatory sequences from the Oct4 gene control
expression of GFP (Oct4::GFP). This transgene is not expressed in somatic tissues, which
are therefore non-fluorescent. However, recent reprogramming studies with defined
transcription factors, cell fusion and nuclear transfer have each demonstrated that
Egli et al. Page 4
Curr Biol. Author manuscript; available in PMC 2012 April 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
reactivation of the Oct4::GFP reporter is a rigorous indicator of complete reprogramming
[11, 19, 20].
CD4+ T-cells were isolated from the spleen and lymph nodes of transgenic Oct4::GFP mice
as described previously [21]. FACS analysis of these preparations confirmed that more than
92% of the cells were indeed CD4+ T-lymphocytes. For T-cell chromosomes transfer,
cultures of purified T-cells were stimulated to enter mitosis with antibodies directed against
CD3ε and CD28, and arrested there with nocadazole. Like other somatic cells, T-cells did
not express Oct4::GFP (Fig. 4a). As with ES donor cells, we found that mitotic T-cell
chromosomes could be readily transferred into embryonic blastomeres at the two-cell stage.
Following chromosome transfer, embryos efficiently underwent cleavage and could develop
to the blastocyst stage (Table 1). 20 hours after chromosome transfer, we found that 24/67
embryos developed to the 6 to 8-cell stage and that 24/24 (100%) of these embryos
contained cells expressing GFP. Oct4::GFP expression indicated that these cells carried the
T-cell donor chromosomes and that these chromosomes had been successfully
reprogrammed (Fig. 4b). After chromosome transfer, we found that Oct4::GFP continued to
be highly expressed within a subset of cells in morula stage and blastocyst stage embryos,
indicating that reprogramming was stable (Fig. 4b).
In summary, our chromosome transfer studies demonstrate that reprogramming activities
persist in the blastomeres of cleavage stage embryos and that these activities are sufficient to
allow the derivation of ES cell lines, the generation of chimeric “cloned” animals and the
reprogramming of terminally differentiated nuclei. This is a particularly interesting finding
because the proteins and transcripts within the two-cell blastomeres, just before their mitotic
division to the 4-cell stage, are substantially different from those present in either the
fertilized zygote or oocyte [22, 23]. We found that Oct4::GFP was reactivated within twenty
hours following lymphocyte chromosome transfer at roughly the same time and stage that it
would have been activated in a normally fertilized embryo. Taken together, these results
imply that the blastomeres of a two-cell embryo can reprogram the incoming donor
chromosomes to a state similar to that of the recipient blastomere. The reprogrammed cell
then goes forward from that developmental stage, rather than reverting to some more
primitive, oocyte or zygote-like transcriptional program before proceeding.
The finding that oocytes, zygotes, embryonic blastomeres and ES cells can each reprogram
differentiated cells indicates that reprogramming activities persist through preimplantation
development. When our results are combined with the recent observations that cell type
specific transcription factors can exact reprogramming [24, 25] it suggests, that if the proper
nuclear or chromosome transfer method could be developed, almost any cell might be
reprogrammed into another. In fact it may be that the reprogramming activities in a
particular cell type are one and the same with the transcription factors that specify its
identity.
The generation of human ES cell lines by nuclear transfer is still a high priority. Only
isogenic cell lines produced by various reprogramming approaches will allow the
effectiveness and utility of the different methods to be accurately compared. Our results
using mouse embryos suggest that cleavage stage human embryos are an important
unexplored resource for nuclear transfer studies. Human embryos are commonly frozen at
the 4 to 8 cell stage. Importantly, a single blastomere from a 4-cell human embryo is roughly
the same size as the mouse zygote and a blastomere from a human 8-cell embryo is similar
in diameter to a blastomere from the 2-cell mouse embryo. Thus, micromanipulation
approaches similar to those described in this study may be feasible with the most readily
available discarded human embryos. Sourcing this material for nuclear transfer studies will
be considerably more routine than obtaining fresh human oocytes, or even frozen zygotes.
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Experimental Procedures
The method followed largely the protocol of chromosome transfer into mitotic mouse
zygotes [11]. Briefly, zygotes were collected from mated BDF1 females 20–24h post hCG
and cultured to the 2-cell stage. 48h – 50h post hCG 2-cell stage embryos were cultured in
the presence of 0.2µg/ml nocodazole to arrest them in mitosis. For removal of the donor cell
genome, mouse embryos were placed on the heated stage of a microscope in HCZB with
slightly lower nocodazole concentrations, between 0.02–0.04 µg/ml, and high cytochalasinB
concentrations of about 10µg/ml to maximize fluidity of the cytoplasm. Under these low
nocodazole concentrations mouse blastomeres arrest in mitosis with a spindle (Supplemental
Figure 1) that can conveniently be removed (Supplemental Movie). Enucleation and transfer
of a new genome was done between 50 and 57h post hCG (Supplemental Movie). The
survival rate of the transfer was 136/244 (56%). After manipulation, embryos were cultured
in KSOM at 37deg. C in 5% CO2. Male ES cells transgenic for pCAGGS:H2B-cherry were
used as donors.
Equipment used consisted of a Nikon microscope equipped with a Narishige
micromanipulator. Details of the microscope setup are essentially as after nuclear transfer
into mouse [26]oocytes [27].
Mouse blastocysts were stained using the Oct3/4 antibody (Santa Cruz sc5279) at a dilution
of 1:200. Cell numbers were quantified with the Imaris program.
CD4+ T-cells were isolated as previously described [21]. Briefly, total splenocytes and
lymph node cells were harvested from 6–10 week old B6jcBA-Tg(Pou5fI-EGFP)2Mnn/J or
H2B-GFP transgenic mice. The cells were labeled with an antibody cocktail, consisting of
antibodies against CD8, CD11b, CD45R/B220, CD49b, and TER-119 (IMag Mouse CD4+
T Lymphocyte Enrichment Set – DM, BD Pharmingen). In order to enrich for CD4+ T cells,
negative selection was performed. Labeled cells were magnetically depleted according to the
protocol of the supplier. The negative selection was performed a second time on the
enriched fraction in order to increase purity of CD4+ T cells. CD4+ T cells purity was higher
than 92 % and the patterns of flow cytometry to check for quality of the enrichment was
consistent with the data shown in the supplier's technical data sheet. Isolated CD4+ T cells
were grown in suspension culture in 6-well plates with a density of a million cells per well
in 5 ml/well of complete RPMI media. The plates were pre-coated with 1 µg/ml of each anti-
CD3ε and anti-CD28 antibodies to stimulate expansion of T-cells. 1–3 days after culture, T-
cells were at maximal rates of proliferation and were arrested in mitosis by incubation with
0.1µg/ml nocodazole for 8 hours. Mitotic T-cells (1–10% of all T cells) were selected for
transfer into blastomeres. Experiments with animals were performed in accordance with the
guidelines established by the Harvard University/Faculty of Arts and Sciences IACUC for
the humane care and use of animals in research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chromosome transfer into mitotic blastomeres
a, Stages of development from the unfertilized oocytes to the 2-cell stage embryo. Oocytes
in meiosis and zygotes in mitosis are suitable for nuclear transfer, but not zygotes in
interphase or even 2-cell stage embryos in interphase. Whether 2-cell stage embryos in
mitosis can be used for transfer of a genome from a more differentiated cell is addressed
here. b, 2-cell stage embryo in interphase 54h post hCG (human chorionic gonadotropin, a
hormone stimulating ovulation). c, Blastomeres in mitosis 55h post hCG. d, One blastomere
had the genome removed in mitosis. e, One of the two blastomeres transferred with mouse
ES cells expressing H2B-cherry. f, A 4-cell stage embryo 12h post transfer. g, Morula at 28h
post transfer, composed of 8 cells, 4 of which are derived from the transferred blastomere.
H) Blastocyst at 48h post transfer. PB= polar body.
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Figure 2. Development after transfer into a fused 2-cell stage embryo
A) Schematic representation of the experiment: 2-cell stage embryos are fused at interphase
to form a tetraploid 1-cell stage embryo. These chromosomes will assemble in a spindle at
the next mitosis, which can be removed and replace with a diploid genome. These embryos
then cleave and develop to the balstocyst stage (B).
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Figure 3. Mice and stem cell lines produced by blastomere reprogramming
a, Contribution of cells derived from the transferred blastomere marked by H2B-cherry to
ICM and TE lineages at the blastocyst stage. Oct4 and H2B-cherry double positive cells are
marked with a asterisk. b, quantification of H2B-cherry cells in TE and ICM (red columns).
Total number of cells is indicated above each column. The total number of Oct4 positive
cells as a marker of the ICM fate is 23% (blue column) at the expanded blastocyst stage.
Bars indicate standard deviations. c, Contribution to full-term development of blastomeres
transferred in mitosis. d, Contribution of cells derived from transferred (red) and
nontransferred blastomere (dark) to a portion of the intestinal tube and the lung. e, Stem
cells derived from chimeric blastocysts. P1= passage1 after manual picking of the ICM
outgrowth. f, Karyotype of stem cells, showing a normal mouse karyotype of 40
chromosomes. Each chromosome is indicated with an arbitrary number of 1–40. g, Oct4
expression in embryonic stem cells derived after chromosome transfer, alkaline phosphatase
staining, and SSEA-1 expression. h, chimeric mouse after injection of ES cells into BDF2
blastocysts. Tissue derived from the ES cell is brown, Tissue derived from the injected
embryo is dark grey.
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Figure 4. Blastomeres can reprogram terminally differentiated T-cells
a, Mitotic CD4+ T-cell population. Donor T-cells do not show expression of an Oct4::GFP
transgene. b, Upon transfer of a mitotic T cell into a blastomere in mitosis, development
occurs and the Oct4::GFP transgene is reactivated within hours after transfer.
Developmental progression to the blastocyst stage.
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